Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 sep 2016 - 07:00
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model
Bericht
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model
In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhances resolvin D2, an important lipid mediator which contributes to termination of inflammatory processes
HALLE (SAALE), Germany, 07 September 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), today announced new findings for its Glutaminyl Cyclase (QC) inhibitor in an inflammation animal model. Data were generated in collaboration with Ambiotis SAS (Toulouse, France) and will be presented at upcoming scientific conferences.
Gerelateerde downloads
Datum laatste update: 01 september 2024